(place patient label here)

Patient Name:_____

Order Set Directions:
- (√)- Check orders to activate; Orders with pre-checked box ☑ will be followed unless lined out.
- Initial each place in the pre-printed order set where changes such as additions, deletions or line outs have been made
- Initial each page and Sign/Date/Time last page

BENEFIS HEALTH SYSTEM

Benefis HOSPITALS

PROVIDER ORDERS

Diagnosis: _____

Allergies with reaction type: _____

POINT STUDY PROTOCOL# ORDERS   Version 2   1/22/2014

Protocol: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

Principal Investigator: Dennis Dietrich, MD 24 hr Cell: 788-9770 or message 455-2570

Study Coordinator: Laura Armstrong Office :   455-2583   Message: 455-2583: Cell 788-7610

Study Clinical Coordinating Center: Mary Farrant 415-502-2096

Emergency contact for eligibility and unblinding and medical monitor:

Dr. Clay Johnston: 866-94POINT (866-947-6468)

Site number: 043

_____Date and time of onset:_____

_____ABCD2 score=_____

_____NIHSS score=_____

_____Patient study ID number:_____

_____Study medication randomization code:_____

_____ Randomization form scanned to pharmacy at: 455-4980

_____ Pharmacy called at Pharmacy number 455-5430 to dispense stat medication to POINT study team member.

Clopidogrel 75 mg vs placebo tablets

Patient to receive 8 tablets stat.

Patient to receive aspirin:_____ mg stat.

Patient to receive 75 mg vs placebo tablets daily for 89 days and label for discharge

Aspirin 162 mg for 4 days then 81 mg daily and label for discharge

Initials_____

(place patient label here)

Patient Name: _____

Prohibited concomitant medications (contact Dr. Dietrich to discuss if clinically necessary).

Nonsteroidal anti-inflammatory agents, including celecoxib

-Open label clopidogrel

-Aggrenox

-Heparin, low molecular weight heparin (Arixtra, Lovenox, etc)

-Warfarin, dabigatran

-t-PA within the past 7 days in an exclusion to enrollment

Prior to administration, discuss the need for the following medications:

Proton pump inhibitors, esomeprazole (NEXIUM), cimetidine (TAGAMET), fluconazole (DIFLUCAN), ketoconazole (NIZORAL), voriconazole (VFEND), etravirine (INTELENCE), felbamate (FELBATOL), fluoxetine (PROZAC), and fluvoxamine (LUVOX).

If proton pump inhibitor therapy is necessary, give pantoprozole (PROTONIX).

On discharge schedule to be seen in follow up for POINT trial within 90 days at Advanced Neurology Specialists. Call research department at 452-2583.

Provider Signature:_____Date:_____Time:_____